{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:46:07Z","timestamp":1784133967520,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1038\/s41401-020-00550-y","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T03:04:24Z","timestamp":1604545464000},"page":"1368-1375","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy"],"prefix":"10.1038","volume":"42","author":[{"given":"Chen-yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-cheng","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-qin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-ya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-liang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-he","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-qin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"key":"550_CR1","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1158\/1078-0432.CCR-17-2439","volume":"24","author":"J Huang","year":"2018","unstructured":"Huang J, Xu B, Mo H, Zhang W, Chen X, Wu D, et al. Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma. Clin Cancer Res. 2018;24:1296\u2013304.","journal-title":"Clin Cancer Res"},{"key":"550_CR2","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A, Keam SJ. Camrelizumab: first global approval. Drugs. 2019;79:1355\u201361.","journal-title":"Drugs."},{"key":"550_CR3","unstructured":"AiRuiKa\u00ae. [package insert], Lianyungang, China: Jiangsu Hengrui Medicine Co. Ltd. 2019."},{"key":"550_CR4","doi-asserted-by":"publisher","first-page":"7363","DOI":"10.1158\/1078-0432.CCR-19-1680","volume":"25","author":"Y Song","year":"2019","unstructured":"Song Y, Wu J, Chen X, Lin T, Cao J, Liu Y, et al. A single-arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical hodgkin lymphoma. Clin Cancer Res. 2019;25:7363\u20139.","journal-title":"Clin Cancer Res"},{"key":"550_CR5","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","volume":"19","author":"W Fang","year":"2018","unstructured":"Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018;19:1338\u201350.","journal-title":"Lancet Oncol"},{"key":"550_CR6","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/cncr.31855","volume":"125","author":"J Huang","year":"2019","unstructured":"Huang J, Mo H, Zhang W, Chen X, Qu D, Wang X, et al. Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China. Cancer. 2019;125:742\u20139.","journal-title":"Cancer."},{"key":"550_CR7","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.dld.2019.07.005","volume":"51","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Zhou Y, Hu K, Li Z, Wang Z, Huang Y. Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib. Dig Liver Dis. 2019;51:1488\u201390.","journal-title":"Dig Liver Dis"},{"key":"550_CR8","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.2147\/DDDT.S243787","volume":"14","author":"JD Lickliter","year":"2020","unstructured":"Lickliter JD, Gan HK, Voskoboynik M, Arulananda S, Gao B, Nagrial A, et al. A first-in-human dose finding study of camrelizumab in patients with advanced or metastatic cancer in Australia. Drug Des Devel Ther. 2020;14:1177\u201389.","journal-title":"Drug Des Devel Ther"},{"key":"550_CR9","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41416-018-0100-3","volume":"119","author":"H Mo","year":"2018","unstructured":"Mo H, Huang J, Xu J, Chen X, Wu D, Qu D, et al. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. Br J Cancer. 2018;119:538\u201345.","journal-title":"Br J Cancer"},{"key":"550_CR10","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/cpt.628","volume":"101","author":"Y Wang","year":"2017","unstructured":"Wang Y, Booth B, Rahman A, Kim G, Huang SM, Zineh I. Toward greater insights on pharmacokinetics and exposure-response relationships for therapeutic biologics in oncology drug development. Clin Pharmacol Ther. 2017;101:582\u20134.","journal-title":"Clin Pharmacol Ther"},{"key":"550_CR11","first-page":"295","volume":"36","author":"M Czarkowski","year":"2014","unstructured":"Czarkowski M. [Helsinki Declaration\u2013next version]. Pol Merkur Lekarski. 2014;36:295\u20137.","journal-title":"Pol Merkur Lekarski"},{"key":"550_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1208\/s12248-012-9373-2","volume":"14","author":"RJ Keizer","year":"2012","unstructured":"Keizer RJ, Zandvliet AS, Beijnen JH, Schellens JH, Huitema AD. Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses. AAPS J. 2012;14:601\u201311.","journal-title":"AAPS J"},{"key":"550_CR13","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1038\/psp.2013.26","volume":"2","author":"W Byon","year":"2013","unstructured":"Byon W, Smith MK, Chan P, Tortorici MA, Riley S, Dai H, et al. Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacomet Syst Pharmacol. 2013;2:e51.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"550_CR14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/0014-5793(74)80734-9","volume":"44","author":"C Fajszi","year":"1974","unstructured":"Fajszi C, Endrenyi L. New linear plots for the separate estimation of Michaelis-Menten parameters. FEBS Lett. 1974;44:240\u20136.","journal-title":"FEBS Lett"},{"key":"550_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10928-019-09635-6","volume":"46","author":"M Ahamadi","year":"2019","unstructured":"Ahamadi M, Largajolli A, Diderichsen PM, de Greef R, Kerbusch T, Witjes H, et al. Operating characteristics of stepwise covariate selection in pharmacometric modeling. J Pharmacokinet Pharmacodyn. 2019;46:273\u201385.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"550_CR16","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/biomet\/asr023","volume":"98","author":"MC Donohue","year":"2011","unstructured":"Donohue MC, Overholser R, Xu R, Vaida F. Conditional Akaike information under generalized linear and proportional hazards mixed models. Biometrika. 2011;98:685\u2013700.","journal-title":"Biometrika."},{"key":"550_CR17","doi-asserted-by":"crossref","unstructured":"Bonate PL. The art of modeling. In: Bonate PL, editor. Pharmacokinetic-pharmacodynamic modeling and simulation.v 20, 2nd ed. Boston, MA: Springer; 2011. p. 17.","DOI":"10.1007\/978-1-4419-9485-1"},{"key":"550_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/BF01061469","volume":"20","author":"JW Mandema","year":"1992","unstructured":"Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic\u2013pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992;20:511\u201328.","journal-title":"J Pharmacokinet Biopharm"},{"key":"550_CR19","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1177\/0091270003253624","volume":"43","author":"EI Ette","year":"2003","unstructured":"Ette EI, Williams PJ, Kim YH, Lane JR, Liu MJ, Capparelli EV. Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol. 2003;43:610\u201323.","journal-title":"J Clin Pharmacol"},{"key":"550_CR20","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s40262-020-00874-2","volume":"59","author":"A Bensalem","year":"2020","unstructured":"Bensalem A, Ternant D. Pharmacokinetic variability of therapeutic antibodies in humans: a comprehensive review of population pharmacokinetic modeling publications. Clin Pharmacokinet. 2020;59:857\u201374.","journal-title":"Clin Pharmacokinet"},{"key":"550_CR21","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s40425-019-0791-x","volume":"7","author":"CS Shemesh","year":"2019","unstructured":"Shemesh CS, Chanu P, Jamsen K, Wada R, Rossato G, Donaldson F, et al. Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. J Immunother Cancer. 2019;7:314.","journal-title":"J Immunother Cancer"},{"key":"550_CR22","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/cpt.982","volume":"103","author":"PG Baverel","year":"2018","unstructured":"Baverel PG, Dubois VFS, Jin CY, Zheng Y, Song X, Jin X, et al. Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status. Clin Pharmacol Ther. 2018;103:631\u201342.","journal-title":"Clin Pharmacol Ther"},{"key":"550_CR23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00280-019-03771-z","volume":"83","author":"M Osawa","year":"2019","unstructured":"Osawa M, Hasegawa M, Bello A, Roy A, Hruska MW. Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers. Cancer Chemother Pharmacol. 2019;83:705\u201315.","journal-title":"Cancer Chemother Pharmacol"},{"key":"550_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/psp4.12139","volume":"6","author":"M Ahamadi","year":"2017","unstructured":"Ahamadi M, Freshwater T, Prohn M, Li CH, de Alwis DP, de Greef R, et al. Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-PD-1 monoclonal antibody in advanced solid tumors. CPT Pharmacomet Syst Pharmacol. 2017;6:49\u201357.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"550_CR25","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"NL Dirks","year":"2010","unstructured":"Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:633\u201359.","journal-title":"Clin Pharmacokinet"},{"key":"550_CR26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/biomedicines8050096","volume":"8","author":"J Cho","year":"2020","unstructured":"Cho J, Park J, Tae G, Jin MS, Kwon I. The minimal effect of linker length for fatty acid conjugation to a small protein on the serum half-life extension. Biomedicines. 2020;8:96.","journal-title":"Biomedicines."},{"key":"550_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40272-020-00382-7","volume":"22","author":"ZH Temrikar","year":"2020","unstructured":"Temrikar ZH, Suryawanshi S, Meibohm B. Pharmacokinetics and clinical pharmacology of monoclonal antibodies in pediatric patients. Paediatr Drugs. 2020;22:199\u2013216.","journal-title":"Paediatr Drugs"},{"key":"550_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40425-017-0242-5","volume":"5","author":"T Freshwater","year":"2017","unstructured":"Freshwater T, Kondic A, Ahamadi M, Li CH, de Greef R, de Alwis D, et al. Evaluation of dosing strategy for pembrolizumab for oncology indications. J Immunother Cancer. 2017;5:43.","journal-title":"J Immunother Cancer"},{"key":"550_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40262-019-00804-x","volume":"59","author":"K Ogasawara","year":"2020","unstructured":"Ogasawara K, Newhall K, Maxwell SE, Dell\u2019Aringa J, Komashko V, Kilavuz N, et al. Population pharmacokinetics of an anti-PD-L1 antibody, durvalumab in patients with hematologic malignancies. Clin Pharmacokinet. 2020;59:217\u201327.","journal-title":"Clin Pharmacokinet"},{"key":"550_CR30","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/jcph.1324","volume":"59","author":"X Wang","year":"2019","unstructured":"Wang X, Ludwig EA, Passarell J, Bello A, Roy A, Hruska MW. Population pharmacokinetics and exposure-safety analyses of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma. J Clin Pharmacol. 2019;59:364\u201373.","journal-title":"J Clin Pharmacol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-00550-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-00550-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-00550-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:02:48Z","timestamp":1684602168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00550-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["550"],"URL":"https:\/\/doi.org\/10.1038\/s41401-020-00550-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.06.30.180117","asserted-by":"object"}]},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,5]]},"assertion":[{"value":"7 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GLM, DX and YYW are employees of Jiangsu Hengrui Medicine Co. Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}